ArticleFrontiers in psychiatry2026
Treatment non-persistence in children and adolescents with Tourette syndrome newly treated with dopamine D2 receptor modulators.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dopamine D2 receptor antagonists/partial agonists (D2RAs), including the US Food and Drug Administration-approved Tourette syndrome (TS) agents haloperidol, pimozide, and aripiprazole and other antipsychotics with dopamine D2 receptor-modulating properties, are prescribed for TS. This retrospective real-world study compared adverse events (AEs) and health care resource utilization (HCRU) between pediatric patients with TS newly treated versus not treated with D2RAs. Methods: Data were analyzed retrospectively from an electronic health records database (TriNetX Dataworks-USA Network) containing information for >119 million individuals. Two cohorts aged 6 to 17 years, from 2011-2021, were identified: a D2RA-exposed cohort indexed at first D2RA medication record with TS diagnosis during baseline (18 months before and including index) and a D2RA-nonexposed cohort indexed on a randomly selected TS diagnosis record (2011-2021) with no D2RA record during baseline or follow-up (18 months after index). Monthly D2RA use was estimated, assuming 30-day coverage into the subsequent month; incident AEs and HCRU were evaluated during follow-up using medication records, diagnosis codes, anthropometric measurements, and/or laboratory results. Results: Analyses included 1684 individuals per exact-matched cohort. In the D2RA-exposed cohort, documented D2RA medication records declined by Month 3 (38.8% of patients with a D2RA record) through Month 18 (17.9%). After adjustment for measured demographic and baseline characteristics, the D2RA-exposed cohort had higher recorded odds of incident AEs grouped as mild (e.g., sleep disorder; odds ratio [95% CI], 3.36 [2.68-4.20]), moderate (e.g., QT prolongation; 2.30 [1.65-3.20]), and severe (e.g., tardive dyskinesia; 3.01 [2.18-4.16]; all Discussion: Children and adolescents with TS newly treated with a D2RA showed substantial decline in documented D2RA medication records over follow-up and had higher recorded odds of AEs and HCRU rates than did those without D2RA exposure. These findings should be interpreted as associational rather than causal effects and may reflect residual confounding by indication, differential monitoring, and/or greater underlying disease severity/complexity in the treated cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.